Singapore, Nov. 28 -- Singapore-based startup Patronus Biotech has announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant programme to support affordable access and use in global health.

The funding will enable the evaluation of an innovativeU-VLP(R)vaccine candidate, LYB014, which targets multiple stages of the most deadly form of malaria parasite's life cycle; as well as a new, low cost, highly pure adjuvant manufactured from synthetic components.

Patronus Biotech's has developed a world first malaria vaccine simultaneously targeting all three critical stages of theP. falciparumlife cycle, showing promising opportunity to provide more effective and broad protection. The vacc...